Theriva Biologics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 19.69 million compared to USD 14.27 million a year ago. Basic loss per share from continuing operations was USD 1.31 compared to USD 1.9 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.331 USD | -8.56% | -11.50% | -23.04% |
May. 23 | Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment | MT |
May. 07 | Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.04% | 6.25M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022